• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[The clinical and prognostic value of inversion of the PSA/PAP ratio in prostatic cancer].

作者信息

Morote Robles J, Lorente J A, Reig C, López Pacios M A, de Torres J A, Soler Roselló A

机构信息

Servicio de Urología, Hospital General Universitario Vall d'Hebrón, Barcelona.

出版信息

Actas Urol Esp. 1994 May;18(5):559-61.

PMID:7521563
Abstract

The inversion of PSA/PAP ratio is not common in patients with prostate cancer. Of 215 patients, 7 showed PSA levels below those of PAP (3.2%). All patients had metastatic disease at the time of diagnosis, 57% in multiple organs and tissues, with a Gleason value in all cases 4. Forty-three percent showed no early response to hormone therapy; mean survival interval recorded in these 7 patients was 21 months. Such a situation may suggest a poor prognosis for this neoplasia.

摘要

相似文献

1
[The clinical and prognostic value of inversion of the PSA/PAP ratio in prostatic cancer].
Actas Urol Esp. 1994 May;18(5):559-61.
2
Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.前列腺特异性抗原/前列腺酸性磷酸酶比值是IV期前列腺癌患者的重要预后因素。
Urology. 2007 Oct;70(4):702-5. doi: 10.1016/j.urology.2007.05.019.
3
The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases.前列腺切除术前前列腺酸性磷酸酶对预测根治性前列腺切除术病例的病理分期和复发的当代价值。
J Urol. 1998 Mar;159(3):935-40.
4
Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.肿瘤标志物。局限性前列腺癌诊断与预后参数共识会议。瑞典斯德哥尔摩,1993年5月12 - 13日。
Scand J Urol Nephrol Suppl. 1994;162:73-87; discussion 115-27.
5
[Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].[前列腺腺癌在诊断时发生转移的演变及预后因素]
Actas Urol Esp. 1997 Sep;21(8):724-36.
6
[The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].[前列腺特异性抗原在局限性前列腺腺癌诊断中的作用。奈良泌尿肿瘤研究组]
Hinyokika Kiyo. 1996 Oct;42(10):795-804.
7
Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.前列腺特异性抗原倍增时间可预测接受联合放疗和激素治疗的前列腺癌患者的临床结局和生存率。
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):456-62. doi: 10.1016/j.ijrobp.2005.03.008.
8
Markers of undiagnosed incidental cancer in comparison with clinical prostatic cancer.未诊断的偶然癌标志物与临床前列腺癌的比较。
J Med. 2000;31(1-2):101-10.
9
The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.前列腺酸性磷酸酶和前列腺特异性抗原作为前列腺癌血清标志物的价值。
Int Urol Nephrol. 1993;25(3):271-8.
10
[Value of serum PSA and PAP measurement with newly developed latex turbidimetric immunoassay].[采用新开发的乳胶比浊免疫分析法测定血清PSA和PAP的价值]
Hinyokika Kiyo. 1995 Jun;41(6):439-45.